Carisma Therapeutics Appoints Renowned Oncologist as Chief Medical Officer

Carisma Therapeutics

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has named Eugene P. Kennedy, M.D., F.A.C.S., as its new Chief Medical Officer. Dr. Kennedy, an esteemed oncologist with over 15 years of experience in the clinical and industry sectors, is tasked with leading Carisma’s clinical development, regulatory approvals, and medical affairs.

Steven Kelly, President and CEO of Carisma, expressed enthusiasm for Dr. Kennedy’s appointment, highlighting his extensive background in oncology and a successful track record in conducting clinical trials for solid tumors. “Gene’s depth of expertise and leadership in oncology will be instrumental in advancing our clinical programs and bringing innovative treatments to patients,” Kelly stated.

Dr. Kennedy joins Carisma at a critical juncture as the company advances its anti-HER2 program through clinical development. Reflecting on his new role, Dr. Kennedy shared his excitement about contributing to Carisma’s pioneering work in engineered macrophages and the potential to significantly impact patient care. “Carisma’s focus on developing new therapeutic modalities aligns perfectly with my lifelong mission to explore treatments that can transform lives,” said Dr. Kennedy.

His impressive career includes significant stints as Chief Medical Officer at Galera Therapeutics, where he led the development of innovative radiotherapy treatments, and at Innovative Cellular Therapeutics, where he was pivotal in moving solid tumor CAR T-cell therapy into clinical trials. Dr. Kennedy also contributed his expertise to Lumos Pharma and NewLink Genetics, driving clinical strategy and overseeing extensive trial programs across various cancer therapies.

Before entering the biotech industry, Dr. Kennedy served as Associate Professor of Surgery at Thomas Jefferson University, enriching his academic credentials with practical leadership in pancreatic and hepatobiliary surgery. His educational background includes a bachelor’s degree from the University of Virginia and an M.D. from the Medical College of Virginia.

READ:  AMETEK Elevates Patrick L. Williams to Lead MRO Division, Announces Quarterly Dividend

Dr. Kennedy’s appointment aims to accelerate Carisma Therapeutics’ efforts in cancer research and treatment. With his leadership, Carisma seeks to develop groundbreaking therapies that offer new hope to patients battling cancer.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.